

## ASX RELEASE

### Scheme update – Volpara Obtains Final Orders for Scheme of Arrangement

Wellington, NZ, 3 May 2024: [Volpara Health Technologies Limited](#) (“Volpara” or “the Company”; ASX:VHT) advises that it has obtained final orders from the New Zealand High Court approving the scheme of arrangement (the “Scheme”), with Lunit Inc (“Lunit”).

As the Scheme is now legally binding, Volpara will request that its shares be suspended from the close of trading today to facilitate the implementation of the Scheme. Volpara will further request that the suspension continue pending the implementation of the Scheme, which is expected to occur on Tuesday, 21 May 2024, following which Volpara will request that ASX delist Volpara from the close of trading on the day following the Implementation Date.

Subject to remaining customary implementation conditions being satisfied or waived (to the extent capable of waiver), the Scheme timetable is:

Date and time	Event
Friday, 3 May 2024 (AEST), close of trading	Last day of trading in Volpara shares on the ASX
7:00 pm on Monday, 13 May 2024 (AEST)	Scheme Record Date for determining entitlements to participate in the Scheme
Tuesday, 21 May 2024 (AEST)	Implementation Date – Lunit acquires all of the shares in Volpara and pays the Scheme consideration for those shares
Wednesday, 22 May 2024 (AEST), close of trading	Cessation of quotation of Volpara shares and delisting of Volpara from the ASX, subject to ASX approval

Holders of Volpara shares at the Scheme Record Date will be entitled to receive the Scheme consideration, which will be paid on the Implementation Date. The Scheme consideration is AU\$1.15 per Scheme share.

#### Authorisation & Additional Information

This announcement was authorised by the CEO & MD of Volpara Health Technologies Limited.

**ENDS**

For further information please contact:

**Corporate enquiries**

Teri Thomas, CEO & MD

Volpara Health Technologies

[teri.thomas@volparahealth.com](mailto:teri.thomas@volparahealth.com)

t: +64 4 499 6029

**Investor relations**

Shareholder Information Line

Toll: 1300 513 794

AU Toll-free: +61 2 9066 4082

NZ Toll-free: +64 9 889 6570

**Media enquiries**

Clive Mathieson

Cato & Clive

[clive@catoandclive.com](mailto:clive@catoandclive.com)

t: 61 411 888 425

**About Volpara Health Technologies Limited (ASX: VHT)**

Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.

Volpara's focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara's software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in the United States and Australia, Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)